EMA Withdrawn: Pioglitazone Krka (pioglitazone hydrochloride) — Krka, d.d., Novo mesto

View source ↗

Summary

Pioglitazone Krka (pioglitazone hydrochloride) has been withdrawn from the EU market.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Pioglitazone Krka (pioglitazone hydrochloride)

Snippet

Status: Withdrawn. Therapeutic area: Diabetes Mellitus, Type 2. MAH: Krka, d.d., Novo mesto. Decision date: 16/09/2014